SecurityBETR / Amplify Snack Brands, Inc. (03211L102)
IndustryFood And Kindred Products
Institutional Owners11
Institutional Shares9,206,014 - 12.00%
Common Shares Outstanding76,745,948 shares (as of 2017-09-30)
Institutional Value$ 72,211,000 USD

Institutional Stock Ownership and Shareholders()

BETR / Amplify Snack Brands, Inc. Institutional Ownership

Amplify Snack Brands, Inc. (NYSE:BETR) has 11 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 9,206,014 shares. Largest shareholders include Discovery Group I, LLC, Janus Capital Management Llc, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., Century Capital Management, LLC, Holland Capital Management Llc, BlackRock Investment Management, LLC, Independent Portfolio Consultants, Inc., BlackRock Advisors LLC, and BlackRock Group LTD.
Amplify Snack Brands, Inc. (NYSE:BETR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-02-10 13F-HR BlackRock Advisors LLC 30,079 15,355 -48.95 487 135 -72.28
2017-05-11 13F-HR HOLLAND CAPITAL MANAGEMENT LLC 138,827 138,827 0.00 1,223 1,166 -4.66
2017-02-10 13F-HR BlackRock Group LTD 21,533 10,138 -52.92 349 89 -74.50
2017-07-06 13F-HR Independent Portfolio Consultants, Inc. 63,370 56,747 -10.45 532 547 2.82
2017-02-14 SC 13G TA XI, L.P.
2018-02-14 13F-HR GLG Partners LP 22,394 0 -100.00 159 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 108,656 109,484 0.76 1,760 965 -45.17
2017-02-10 13F-HR BlackRock Fund Advisors 752,302 879,951 16.97 12,187 7,752 -36.39
2018-04-18 13F-HR/A FNY Partners Fund LP Call 113 0 -100.00 1 0 -100.00
2018-05-11 13F-HR CITIGROUP INC 7,089 0 -100.00 85 0 -100.00
2018-02-14 13F-HR GLG LLC 670,915 0 -100.00 4,757 0 -100.00
2018-04-18 13F-HR/A FNY Partners Fund LP 6,100 0 -100.00 73 0 -100.00
2017-05-16 13F-HR JANUS CAPITAL MANAGEMENT LLC 0 1,829,763 0 15,370
2017-03-16 13F-HR ISRAEL DISCOUNT BANK OF NEW YORK /GFN 1,215 11
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 602,132 851,466 41.41 9,755 7,501 -23.11
2018-02-12 13F-HR Hutchin Hill Capital, LP 249,695 0 -100.00 1,770 0 -100.00
2018-08-14 13F-HR TA ASSOCIATES, L.P. 0 0 0 0
2017-11-13 13F-HR Discovery Group I, LLC 3,487,952 4,918,795 41.02 33,624 34,874 3.72
2017-08-10 13F-HR Century Capital Management, LLC 271,368 394,273 45.29 2,279 3,801 66.78

Related Articles

REPH: Recro Pharma Analysis and Research Report

12h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

13h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

13h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

7 Alternative Consumer Stocks to Buy With 25% Upside

2018-08-15 investorplace
Consumer stocks are on fire so far in 2018 — the Consumer Discretionary Select SPDR ETF (NYSEARCA:XLY) is up 14% year to date through August 13, double the performance of the S&P 500 — and that’s got Goldman Sachs (NYSE:GS) singing the praises of 7 companies that include a hotel chain, food services business, a casino operator, and several more. (21-0)

Hershey's (HSY) Margin for Growth Plan to Drive Q2 Earnings

2018-07-19 zacks
The Hershey Company (HSY - Free Report) is scheduled to release second-quarter 2018 results on Jul 26. We expect the company to continue gaining from its cost-saving and productivity improvement efforts. Focus on innovation and brand enhancing initiatives are also likely to drive Hershey’s performance amid hurdles. (4-0)

Should Hershey Buy Tootsie Roll?

2018-06-22 seekingalpha
We like Hershey's brand, competitive position, pricing power, and ability to extract greater levels of profitability each and every year. (9-0)

7 Women-Led S&P 500 Companies to Own for the Long Haul | InvestorPlace

2018-06-13 investorplace
Just 25% of S&P 500 companies have two or more women on their board of directors. For women looking to become a CEO one day, it’s a big problem. (26-0)

Popcorn to Ruby Bars: Chocolatiers Branch Out to Woo Millennials

2018-06-12 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com (19-0)

CUSIP: 03211L102